livescience - A blood-filtering therapy for preeclampsia is safe for pregnant patients and their babies, according to a new pilot study.
AI Summary: Early clinical work suggests removing a circulating anti‑angiogenic factor can safely extend pregnancies in severe preeclampsia. Researchers used targeted extracorporeal filtration to lower soluble Fms‑like tyrosine kinase‑1 (sFlt‑1) levels, improving maternal and fetal stability long enough to delay delivery and reduce immediate risks, meriting larger controlled trials.
Researchers grow liver tissue in patients' bodies; study now under scrutiny / 6 wks
Engineered esophagus tissue offers new hope for children with absent organs / 2 months
Studies neglect women's experiences in childbirth and breastfeeding research / 15 days
New science pushes erectile disorder treatment beyond Viagra / 4 wks
FDA approves Rocket Pharma gene therapy for ultra‑rare immune disorder / 2 months
Grail’s Galleri blood test misses UK study goal; investor jitters / 3 months
UCLA unveils low-cost blood test to detect multiple cancers from one sample / 7 wks
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.